GeoVax Announces Key Staff Appointments
March 07 2022 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, today announced recent key staff
appointments and changes
Jeffrey Welch has been appointed to serve as Head, Process
Development and Manufacturing Operations (consultant). In
this role, Jeff will provide oversight and direction to enhance
GeoVax’s manufacturing capacity of MVA-related products, a key
element in advancing the Company’s current and upcoming clinical
development programs. Jeff brings over 30 years of experience in
biopharmaceutical development and CMC operations, with expertise in
manufacturing process development and technical operations related
to vaccines and specifically related to MVA. Jeff earned a Bachelor
of Science in Chemical Engineering from the Massachusetts Institute
of Technology.
Erica Raiden has been appointed to serve as Director, Clinical
Operations. In this role, Erica will work closely with our CRO
partners and engage with clinical sites to facilitate advancing our
clinical trials, ensuring that our clinical development programs
are aligned with corporate objectives and priorities and proceeding
in a timely manner. Erica brings over 25 years of progressive
experience in clinical project management, regulatory affairs and
scientific research. Erica earned a Bachelor of Science in Biology
from Old Dominion University.
The Company also announced that Mark J. Newman, PhD, Chief
Scientific Officer, is now serving in a full-time capacity, having
previously worked on a part-time basis.
David Dodd, GeoVax President and CEO, commented, “Jeff and Erica
are welcome additions to the GeoVax team, as they each bring a
wealth of knowledge and expertise to these key positions and we
look forward to their valuable contributions. Their appointments
follow the appointment of Dr. Kelly McKee as our Chief Medical
Officer in January and the engagement of CATO SMS as our CRO
partner for our Gedeptin® clinical program. These represent
important steps forward in the strengthening of GeoVax’s
organizational and operational resources to support our advancement
through clinical development and regulatory registration.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms. GeoVax’s
product pipeline includes two ongoing Phase 2 clinical trials of
GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster
vaccine to mRNA vaccines authorized by the U.S. Food and Drug
Administration (FDA) and as a primary vaccine for use in
immunocompromised patients. In addition to GEO-CM04S1 for COVID-19,
GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The
Company is also conducting a Phase 1/2 clinical trial of Gedeptin®
for treatment of head and neck cancer. Gedeptin® has been granted
orphan drug status by the FDA. Additional research and development
programs include preventive vaccines against Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and
malaria, as well as immunotherapies for multiple solid tumors. The
Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventive vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventive vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventive vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventive vaccines will receive regulatory approvals necessary to
be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
registration statement on Form S-1 and the periodic reports on Form
10-Q and Form 10-K that we have filed and will file with the SEC.
Any forward-looking statement made by us herein speaks only as of
the date on which it is made. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future developments or
otherwise, except as may be required by U.S. federal securities
law.
GeoVax Labs, Inc.678-384-7220investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024